Susquehanna International Group’s Avidity Biosciences RNAM Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q1 | – | Sell |
-82,600
| Closed | -$5.96M | – | 13966 |
|
|
2025
Q4 | $5.96M | Sell |
82,600
-331,600
| -80% | -$21.4M | ﹤0.01% | 3751 |
|
|
2025
Q3 | $18M | Buy |
414,200
+340,700
| +464% | +$13.8M | ﹤0.01% | 2311 |
|
|
2025
Q2 | $2.09M | Sell |
73,500
-59,400
| -45% | -$1.77M | ﹤0.01% | 5692 |
|
|
2025
Q1 | $3.92M | Buy |
132,900
+83,500
| +169% | +$2.6M | ﹤0.01% | 4109 |
|
|
2024
Q4 | $1.44M | Buy |
49,400
+11,500
| +30% | +$481K | ﹤0.01% | 6051 |
|
|
2024
Q3 | $1.74M | Sell |
37,900
-60,900
| -62% | -$2.64M | ﹤0.01% | 5558 |
|
|
2024
Q2 | $4.04M | Buy |
98,800
+18,600
| +23% | +$534K | ﹤0.01% | 3799 |
|
|
2024
Q1 | $2.05M | Buy |
80,200
+26,800
| +50% | +$420K | ﹤0.01% | 5278 |
|
|
2023
Q4 | $483K | Buy |
53,400
+26,500
| +99% | +$177K | ﹤0.01% | 8743 |
|
|
2023
Q3 | $172K | Buy |
+26,900
| New | +$232K | ﹤0.01% | 10400 |
|
|
2023
Q2 | – | Sell |
-27,300
| Closed | -$419K | – | 12970 |
|
|
2023
Q1 | $419K | Sell |
27,300
-37,300
| -58% | -$821K | ﹤0.01% | 8995 |
|
|
2022
Q4 | $1.43M | Sell |
64,600
-18,400
| -22% | -$274K | ﹤0.01% | 5390 |
|
|
2022
Q3 | $1.35M | Buy |
83,000
+31,200
| +60% | +$597K | ﹤0.01% | 5849 |
|
|
2022
Q2 | $753K | Buy |
51,800
+12,700
| +32% | +$189K | ﹤0.01% | 7229 |
|
|
2022
Q1 | $722K | Buy |
+39,100
| New | +$664K | ﹤0.01% | 7997 |
|
Other funds holding RNAM
Susquehanna International Group's RNAM Position: Q1 2026 in Review
Susquehanna International Group sold out of Avidity Biosciences (RNAM) in Q1 2026, closing a stake of 268,393 shares — an estimated $19.4M sold.
Susquehanna International Group first reported a position in RNAM in Q3 2020 and held it in 21 quarters. The position peaked at $19.4M in Q4 2025. 1 fund tracked by Wall St. Rank holds RNAM as of Q1 2026.
- Susquehanna International Group reported no remaining Avidity Biosciences position as of Q1 2026 after selling out during the quarter.
- Susquehanna International Group sold 268,393 Avidity Biosciences shares in Q1 2026, an estimated $19.4M.
- Susquehanna International Group first reported a position in Avidity Biosciences in Q3 2020 and held it in 21 quarters.
- Susquehanna International Group's Avidity Biosciences position peaked at $19.4M in Q4 2025.
- 1 fund tracked by Wall St. Rank held Avidity Biosciences as of Q1 2026.
Based on Susquehanna International Group's 13F filing for Q1 2026, filed 15 May 2026.